Method for reducing hook effect in an immunoassay

• US 6,184,042 B1
• Filed: 05/22/1997
• Issued: 02/06/2001
• Est. Priority Date: 05/24/1996
• Status: Expired due to Term

• Current Assignee: Roche Diagnostics GmbH (Roche Holding AG)
• Original Assignee: Boehringer Mannheim GmbH (Roche Holding AG)
• Inventors: Neumann, Ulrich, Lenz, Helmut, Franken, Norbert
• Primary Examiner(s): Eyler, Yvonne
• Assistant Examiner(s): Nichols, Jennifer
• Application Number:
  US08/862,062
• Time in Patent Office: 1,356 Days
• Field of Search: 435/7.1, 435/7.9, 435/7.92, 435/7.93, 435/7.94, 435/962, 436/518, 436/523, 530/387.3
• US Class Current: 436/518
• CPC Class Codes: C07K 16/26 against hormones ; against hormone releasing or inhibiting factors
• CPC Class Codes: G01N 33/6857 Antibody fragments
• CPC Class Codes: G01N 33/76 Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
• CPC Class Codes: Y10S 435/962 Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding

Abstract

In order to extend the measuring range and to reduce the Hook effect in an immunological method of determination of an antigen based on the principle of a sandwich assay it is preferable to use a method which is characterized in that the labelled detection molecule is an oligomer of a binding molecule selected from antibody or/and antibody fragment.

Claims

1. A method for extending the concentration range at which an analyte can be detected in a sample liquid according to the principle of a sandwich assay comprising the step of

a) incubating the sample liquid in the presence of a solid phase with at least two receptors that are each capable of binding to the analyte wherein the first receptor is soluble and the second receptor (i) is bound to a solid phase or (ii) is capable of binding to a solid phase;

and

b) detecting the analyte by determining a label in the solid phase, the liquid phase, or both the solid phase and the liquid phase,

wherein the first receptor is a labeled oligomer of a binding molecule selected from antibodies, antibody fragments, and mixtures thereof, and wherein all of said antibodies and antibody fragments bind to the same antigen, in an amount sufficient to reduce the Hook Effect.

2. Method as claimed in claim 1, wherein

the degree of oligomerization of the first receptor is 2 to 15.

3. Method as claimed in claim 1, wherein

the first receptor carries 1 to 20 labelling groups.

4. Method as claimed in claim 3, wherein

the first receptor carries 2 to 10 labelling groups.

5. Method as claimed in claim 3, wherein

the labelling group is a luminescent metal chelate labelling group.

6. Method as claimed in claim 5, wherein the luminescent metal chelate is selected from the group consisting of ruthenium, rhenium, iridium andosmium chelates.

7. Method as claimed in claim 6, wherein the luminescent metal chelate is a ruthenium chelate.

8. The method as claimed in claim 1, wherein the solid phase is composed of a particulate, magnetic material and is coated with the second receptor or a material which is capable of binding to the second receptor.

9. Method as claimed in claim 1, wherein the determination is carried out in the presence of a labelled first receptor and additional unlabelled analyte-specific receptor.

10. Method of claim 1 wherein the second receptor carries biotin groups and the solid phase carries avidin or streptavidin groups.

11. Method for reducing Hook effect in an immunoassay, comprising carrying out said immunoassay with an oligomeric antibody, wherein said oligomeric antibody comprises a covalently linked conjugate of at least two antibodies, antibody fragments, and/or mixtures therof, the degree of oligomerization being 2-15, wherein all of said antibodies and antibody fragments bind to the same antigen, in an amount sufficient to reduce the Hook effect.

12. The method of claim 11, wherein said conjugate of at least two antibodies, antibody fragments and mixtures thereof are directly linked by a chemical bond.

13. The method of claim 11, wherein said conjugate of at least two antibodies, antibody fragments and/or mixture thereof are linked by a bifunctional linker or spacer molecule.

14. The oligomeric antibody of claim 13, wherein said bifunctional spacer or linker molecule is bis(maleinimido)-methyl ester, dimethyl suberimidate, disuccinimidyl suberate, glutardialdehyde, N-succinimidyl-3-(2-pyridyldithio) propionate, N-5-azido-2-nitrobenzoylsuccinimide, N-succinimidyl (4-iodacetyl)-aminobenzoate, or a combination of maleinimidohexanoyl-succinimidate and S-acetyl-mercaptosuccinic acid anhydride.

15. Method of claim 11 wherein said oligomeric antibody comprises 4 or more paratopes, and wherein said oligomeric antibody carries at least one labeling group.

16. Method of claim 15 wherein the labelling groups are luminescent metal chelate labelling groups.

17. Method of claim 16 wherein the luminescent metal chelate is a ruthenium chelate.

18. Method of claim 15 wherein said oligomeric antibody carries between 2 to 20 labeling groups.

19. Method of claim 11 wherein said oligomeric antibodies comprises antibodies or/and fragments thereof covalently linked to one another.